Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis - Summary - MDSpire
Advertisement
Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis
To evaluate the cardiorenal efficacy of dapagliflozin combined with valsartan in patients with coexisting T2DM and hypertension, specifically comparing it to valsartan monotherapy.
Key Findings:
Combination Group showed greater reductions in systolic and diastolic blood pressure (P < 0.001).
Significant improvements in glycemic control (FPG and 2hPG) in the Combination Group (P < 0.001).
Inflammatory and cardiac biomarkers declined more markedly in the Combination Group (P < 0.05).
Improved echocardiographic measures and renal function in the Combination Group (P < 0.05).
The addition of dapagliflozin to valsartan significantly enhances cardiorenal outcomes compared to valsartan alone in patients with T2DM and hypertension, highlighting its potential role in clinical practice.
Limitations:
Retrospective design may introduce bias, affecting the reliability of the findings.
Limited generalizability due to single-center study, which may not represent broader populations.
Conclusion:
Dapagliflozin combined with valsartan provides superior cardiorenal benefits in patients with T2DM and hypertension, supporting its use in clinical practice.
